Salmon Calcitonin is a peptide with poor oral bioavailability. To assess its potential for oral delivery, Catalent conducted a parallel screening with 2 different technologies targeting duodenal and sublingual biological barriers respectively. Lipid formulations and lyophilized tablet formulations were developed in parallel. Subsequently, based on the animal PK study data, the optimal formulation and dose form was identified which shows the oral bioavailability of Salmon Calcitonin was increased by more than 20 times.